Cetuximab plus XELIRI or XELOX for First-Line Therapy of Metastatic Colorectal Cancer
- 31 March 2008
- journal article
- review article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 7 (2), 110-117
- https://doi.org/10.3816/ccc.2008.n.015
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III studyAnnals of Oncology, 2006
- Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinomaAnnals Of Oncology, 2005
- Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986Journal of Clinical Oncology, 2005
- A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancerAnnals of Oncology, 2005
- Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by ChemotherapyAnnals of Surgery, 2004
- XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2004
- Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabineCancer, 2004
- A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal CancerJournal of Clinical Oncology, 2004
- EGFR and cancer prognosisEuropean Journal Of Cancer, 2001